When can we stop using oral poliovirus vaccine?

Journal of Infectious Diseases

Volumn 192, Issue 12, 2005, Pages 2033-2035

  Hull, Harry F ^a   Minor, Philip D ^b  

^a MINNESOTA DEPARTMENT OF HEALTH   (United States)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ORAL POLIOMYELITIS VACCINE;

EDITORIAL; ERADICATION THERAPY; HIGH RISK POPULATION; INFECTION RISK; POLIOMYELITIS; PRIORITY JOURNAL; VIRUS TRANSMISSION; VIRUS VIRULENCE;

HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; VACCINATION; VIRUS SHEDDING;

EID: 28844438841     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/498171     Document Type: Editorial

References (9)

1. Yoneyama T, Yoshida H, Shimizu H, et al. Neurovirulence of Sabin 1-derived polioviruses isolated from an immunodeficient patient with prolonged viral excretion. Dev Biol (Basel) 2001; 105:93-8.
2. Sutter RW, Caceres VM, Mas Lago P. The role of routine polio immunization in the post-certification era. Bull World Health Organ 2004; 82:31-9.
3. Laassri M, Lottenbach K, Belshe R, et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005; 192:2092-8 (in this issue).
4. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 1997; 175(Suppl 1):S215-27.
5. Fine PE, Oblapenko G, Sutter RW. Polio control after certification: major issues outstanding. Bull World Health Organ 2004; 82:47-52.
6. World Health Organization. Cessation of routine oral polio vaccine (OPV) use after global polio eradication. Framework for national policy makers in OPV-using countries. Geneva: World Health Organization, 2005.
7. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004; 363:1509-13.
8. Hennessey KA, Lago H, Diomande F, et al. Poliovirus vaccine shedding among persons with HIV, Abidjan, Cote d'Ivoire. J Infect Dis 2005; 192:2124-8 (in this issue).
9. Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 2004; 82:3-8.